Dual-listed Kiwi cervical cancer screening company TruScreen has opened a $3 million capital raise, six months after its board warned it might not survive without raising more cash.
Auckland-headquartered TruScreen markets a cervical cancer testing device that uses opto-electronics technology
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).